Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ParpVax2: Niraparib + Ipilimumab in Metastatic Pancreatic Cancer
NCT06747845Phase 2Recruiting
- Sponsor
- Abramson Cancer Center
- Start
- May 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib, ipilimumab in pancreatic adenocarcinoma (PDAC), sponsored by Abramson Cancer Center. Started May 2025; status: recruiting.
02
Drugs
niraparibipilimumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06747845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06747845.